Hamburg's ScreeningPort involved in new Fraunhofer Institute
The Frauenhofer ScreeningPort in Hamburg is to assist the Institute for Translational Medicine and Pharmacology with pharmaceutical drug search and medical data science, according to a press release Thursday (January 7, 2021). Findings from infection research will be processed in Hamburg for medical purposes and industry. This come after the (TMP) branch of Fraunhofer IME became an independent institute with headquarters in Frankfurt am Main and locations in Hamburg and Göttingen on January 1, 2021.
Hamburg to expand expertise in infection research
Prof. Dr. Carsten Claussen, Manager of Fraunhofer ITMP in Hamburg, noted: "The founding of this institute is another step towards expanding application-orientated health research in Hamburg and establishing effective biomedicine." Katharina Fegebank, Senator for Science, Research, Equality in Hamburg, commented: "I am pleased that the Fraunhofer ScreeningPort with the great expertise in drug research that it provides, can contribute to the innovative capacity of the new institute." The objective in Hamburg is to bundle the expertise in infection research even more comprehensively and to expand it sustainably.
New institute to link forward-looking technologies
The Fraunhofer ScreeningPort became part of the Fraunhofer Institute for Molecular Biology and Applied Ecology (IME) based in North Rhine-Westphalia in 2014. Three years later, the Translational Medicine and Pharmacology Project Group was expanded to become part of the Fraunhofer IME. The new Fraunhofer ITMP will implement innovative solutions with competitive advantages and added value for society. The clear objective remains the efficient transfer of innovative ideas into medical practice and training future leaders in biomedical research.